Unveiling a New Ultra Violet-Spectrophotometric Strategy for Simultaneous Quantification of Adapalene and Erythromycin in Powders and Nanocarriers

Background: This study is aimed to establish a novel and reliable UV-visible spectrophotometric method for simultaneous quantification of Adapalene and Erythromycin. Purpose: There is no documented Ultra Violet analysis for these drugs together, especially in nanocarriers. This method is simple, rapid, selective, and precise, suitable for both bulk powders and drug-loaded nanocarriers. Materials and Methods: A Shimadzu Ultra Violet/Visible spectrophotometer model 1800, was used. The optimized analysis condition employed Oxolane: Ortho phosphoric acid (OPA) buffer (30:70% v/v) as the solvent. Results and Discussion: Erythromycin and Adapalene showed peak absorbance at 214 nm and 235 nm, respectively. The method exhibited a linear relationship between concentration and absorbance. Adapalene showed linearity between 0.1-0.5 μg/mL, and Erythromycin between 10-50 μg/mL. High regression coefficients (0.9985 for Adapalene, 0.9981 for Erythromycin) confirmed excellent quantification accuracy. Conclusion: The results confirmed that the excipients present in the nanoformulation did not interfere with the analytical method, indicating its suitability for routine quality control analysis of Erythromycin and Adapalene in both bulk drug substances and formulated products.